TrialThe Korean journal of internal medicine2023

Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: a prospective phase II study.

Dong Won Baek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.